ArticleNeuropsychology2024
Pick a PACC: Comparing domain-specific and general cognitive composites in Alzheimer disease research.
Article in Neuropsychology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 13 citations in OpenAlex.
- Comorbid insomnia and sleep apnea is associated with worse verbal episodic memory in older females.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Trial
- Structural and social determinants of health shape the impact of neurodegeneration and cerebrovascular pathology on cognitive functioning in black adults.Social science & medicine (1982) · 2026Article
- Sensorimotor function as an early marker of cognitive decline and alzheimer's biomarker burden.GeroScience · 2026Article
- Technology-natives and technology-adopters: Age differences in remote cognitive assessment in Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.medRxiv : the preprint server for health sciences · 2026Article
- Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Early syndecan-4 upregulation predicts cognitive and pathological trajectories in Alzheimer disease.Alzheimer's research & therapy · 2026Article
- Grip strength modifies the association between blood-based alzheimer's biomarkers and cognitive function.GeroScience · 2026Article
- The Virtual Kitchen Challenge-Version 2: Validation of a Digital Assessment of Everyday Function in Older Adults.JMIR aging · 2026Article
- Elevated functional magnetic resonance imaging activity in cognitively normal participants predicts future dementia.Brain communications · 2026Article
- Association of Daily Driving Behaviors With Mild Cognitive Impairment in Older Adults Followed Over 10 Years.Neurology · 2025Observational
- The Knight Alzheimer Research Imaging (KARI) dataset: a comprehensive multimodal resource for exploring aging, preclinical, and symptomatic Alzheimer disease pathology.Research square · 2025Article
- Associations of Cerebrospinal Fluid Orexin-A, Alzheimer Disease Biomarkers, and Cognitive Performance.Annals of clinical and translational neurology · 2025Article
- The associations between attentional control, episodic memory, and Alzheimer's disease biomarkers of tau and neurodegeneration.Journal of Alzheimer's disease : JAD · 2025Article
- Predictors and outcomes of fluctuations in the clinical dementia rating scale.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Domain-specific cognitive impairment is differentially affected by Alzheimer disease tau pathologic burden and spread.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.The journal of prevention of Alzheimer's disease · 2024Article
- Remote digital cognitive assessment in a trial-ready Alzheimer's disease cohort: A scalable approach for early intervention studies.Alzheimer's & dementia (New York, N. Y.)Article
- Plasma GFAP and language-network tau mediate the effect of amyloid burden on semantic fluency: A mediation analysis.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Features predicting data exclusion in imaging studies of Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveWe aimed to illustrate how complex cognitive data can be used to create domain-specific and general cognitive composites relevant to Alzheimer disease research.
methodUsing equipercentile equating, we combined data from the Charles F. and Joanne Knight Alzheimer Disease Research Center that spanned multiple iterations of the Uniform Data Set. Exploratory factor analyses revealed four domain-specific composites representing episodic memory, semantic memory, working memory, and attention/processing speed. The previously defined preclinical Alzheimer disease cognitive composite (PACC) and a novel alternative, the Knight-PACC, were also computed alongside a global composite comprising all available tests. These three composites allowed us to compare the usefulness of domain and general composites in the context of predicting common Alzheimer disease biomarkers.
resultsGeneral composites slightly outperformed domain-specific metrics in predicting imaging-derived amyloid, tau, and neurodegeneration burden. Power analyses revealed that the global, Knight-PACC, and attention and processing speed composites would require the smallest sample sizes to detect cognitive change in a clinical trial, while the Alzheimer Disease Cooperative Study-PACC required two to three times as many participants.
conclusionsAnalyses of cognition with the Knight-PACC and our domain-specific composites offer researchers flexibility by providing validated outcome assessments that can equate across test versions to answer a wide range of questions regarding cognitive decline in normal aging and neurodegenerative disease. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.